A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy

Update Il y a 4 ans
Reference: EUCTR2011-004525-27

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C. 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetrapib 100 mg.


Inclusion criteria

  • Heterozygous Familial Hypercholesterolemia